Urovant Sciences® Announces Partnership with Thinx Inc. to Help

$ 9.00

4.7 (159) In stock

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel educational camp

Urovant Sciences® Receives “Best in Category” Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference

US Coalition on Sustainability

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

Sumitovant's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile

Medicare Advantage beneficiaries see better health outcomes

Endpoints News — Genentech touts Tecentriq combo data in liver cancer; Rep. Frank Pallone criticizes noncompliance with trial records law

Urovant Sciences, Inc.: Contact Details and Business Profile

U of T Entrepreneurship Week 2024: 10 startups to watch

Youth Policy-Makers Hub 2022-2023 Cohort – Ontario Council for International Cooperation

Urovant launches overactive bladder awareness campaign

Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022

Myovant Sciences Stock News (MYOV)

Next Science Partnerships - Next Science

Health Innovation Hub (H2i) @ U of T Stress Management & Mental Wellness for Entrepreneurs - Health Innovation Hub (H2i) @ U of T

AI generates proteins with exceptional binding strengths - UW Medicine